Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Clinical trial NCT07742332 · RECRUITING

Trial details

NCT number: NCT07742332
Sponsor: Peng Zhang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR NSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer Radiotherapy Chemotherapy

Start date: 2025-11-25
Primary completion: 2027-11-25
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.